Results 71 to 80 of about 23,013 (189)

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, Volume 20, Issue 8, Page 2114-2128, August 2026.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer – a phase II study

BMC Cancer, 2002
Background 5-fluorouracil remains the standard therapy for patients with advanced/metastatic colorectal cancer. Pre-clinical studies have demonstrated the biological modulation of 5-fluorouracil by methotrexate and leucovorin.
Savage Paul, White Douglas R, Higgs Vetta, Melin Susan A, Tomlinson Shannon K, Case Douglas, Blackstock A William   +6 more
doaj   +1 more source

Assessing the Feasibility of a Self‐Management Intervention for Individuals With Advanced Prostate Cancer and Comorbid Type II Diabetes Mellitus

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Many older adults with cancer have at least one comorbidity. Type II diabetes mellitus (T2DM) is a common comorbidity among patients with prostate cancer (PC) and represents an important consideration in this population. Comorbid T2DM can negatively impact cancer‐specific outcomes for patients, suggesting the need for better ...
Amy L. Shaver, Christina Steinbock‐Malfer, William Tester, Patrick Mille, William K. Kelly, Kevin K. Zarrabi, Costas D. Lallas, Mihir Shah, Rose DiMarco, Emily Brand, Shawntel Brown, Swapnil Sharma, Nikita Nikita, Cindy Cogen, Scott W. Keith, Grace Lu‐Yao   +15 more
wiley   +1 more source

A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis

Radiation Oncology, 2017
Background This study aimed to evaluate the efficacy of a high dose of oral tegafur-uracil (400 mg/m2) plus leucovorin with preoperative chemoradiation of locally advanced rectal cancer and to explore the impact of polymorphisms of cytochrome P 2A6 ...
Sun Young Kim, Ji Yeon Baek, Jae Hwan Oh, Sung Chan Park, Dae Kyung Sohn, Min Ju Kim, Hee Jin Chang, Sun-Young Kong, Dae Yong Kim   +8 more
doaj   +1 more source

Early‐Onset Gastric Cancer as a High‐Risk Disease Entity in the United States: Clinicopathologic Features, Regional Variation, and Outcomes

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Introduction Early‐onset gastric cancer (EOGC), defined as diagnosis before age 45, represents a distinct and increasingly recognized subset of gastric cancer. Emerging evidence suggests that clinical behavior, treatment patterns, and outcomes differ from average‐onset disease, yet these differences remain incompletely characterized.
Dani R. Castillo, Pranati Shah, Derek Tai, Mengni Guo, Max Hazeltine, Sofia Guzman, Daniel Park, Rifat Mannan, Yan Xing, Gagandeep Brar, Mustafa Raoof, Cathy Eng, Shengyang Wu   +12 more
wiley   +1 more source

The evolving landscape of the Warburg effect in gastric cancer: From molecular mechanisms to targeted therapy

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
Hypoxia, oncogenic signaling, transcriptional and epigenetic remodeling, and H. pylori–microbiota interactions drive the Warburg effect in gastric cancer. Enhanced glycolysis and lactate export support biosynthesis, remodel the tumor microenvironment, promote stromal activation and immune suppression, and reveal actionable biomarkers and therapeutic ...
Guanmo Liu, Pan Li, Zizhuo Li, Jie Li, Chenggang Zhang, Yihua Wang, Weiming Kang, Xin Ye   +7 more
wiley   +1 more source

Prognostic and Predictive Role of Circulating Tumor DNA in Locally Advanced Rectal Cancer Managed With Total Neoadjuvant Therapy: A Systematic Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Circulating tumor DNA (ctDNA) has emerged as a promising biomarker of tumor burden and minimal residual disease. As total neoadjuvant therapy (TNT) increasingly supports organ‐preserving strategies in locally advanced rectal cancer (LARC), reliable markers of treatment response are needed.
Faizan Bashir, Qurat‐ul‐Aine Bhat, Jayden Allegakoen, Dorsa Shekouh, Sajida Zaiter   +4 more
wiley   +1 more source

Deep Learning Predicts Imminent Tumor Progression in Advanced Pancreatic Adenocarcinoma Using Serial CT Scans During Chemotherapy

MedComm, Volume 7, Issue 8, August 2026.
A spatiotemporal deep learning model combining serial CT scans and baseline clinical data predicts tumor progression at the next follow‐up visit in advanced PDAC. The model achieved robust performance across internal, external, and prospective cohorts (AUC: 0.74–0.77). This noninvasive approach enables earlier identification of imminent progression and
Jun Cheng, Yize Mao, Shuxiang Huang, Xiaotong Tan, Xiaoping Yi, Xiaoying Du, Qiulin Liu, Jianyao Zhou, Rong Huang, Weijie Chen, Rong Zhang, Lizhi Liu, Wufeng Xue, Ruobing Huang, Youhui Qian, Dong Ni, Wenjun Mao, Tao Qin, Shengping Li, Qiuxia Yang   +19 more
wiley   +1 more source

Comparative study of Valsartan and Leucovorin alone or in combination for renal protection in methotrexate-induced acute kidney injury in rats

Current Issues in Pharmacy and Medical Sciences
Methotrexate (MTX) is a widely used chemotherapeutic and immunosuppressive agent that may induce acute kidney injury (AKI), posing a major clinical challenge.
Jayshree Dawane , Sonali Suryawanshi, Harshita Jain, Priti Dhande, Sandhya Shukla   +4 more
doaj   +1 more source

Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Hematological malignancies remain one of the leading causes of morbidity and mortality despite advances in targeted therapies, immunotherapy, and stem cell transplantation. Emerging evidence indicates that treatment efficacy and toxicity depend not only on the choice of therapy but also on its timing relative to the patient's internal ...
Andrej Belančić, Marko Skelin, Yun Wah Lam, Almir Fajkić, Bruna Perkov‐Stipičin, Rossana Roncato, Ivan Krečak, Marko Lucijanić   +7 more
wiley   +1 more source